Drug-maker Glenmark has formalised an outlicensing deal with Sanofi-aventis to further develop and commercialise the former's novel agents to treat chronic pain, including prospective pain molecule GRC 15300.
The deal breaks a drought of close to two-and-a-half years on the outlicensing front, besides marking a turnaround on the research front for the company. Glenmark will receive an upfront payment of $ 20 million from the Sanofi deal, with milestone and 'double-digit' royalty payments as the molecule is further developed and hits the market. The total value of these payments is pegged at $325 million.
The deal outlines exclusive marketing rights for Sanofi in North America, European Union and
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: